This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Several years ago, Deprez et al.1 reported linkage of occipitotemporal lobe epilepsy and migraine with visual aura to chromosome 9q21-q22 in Belgian families. In this issue of Neurology®, Tikka-Kleemola et al.2 revisit the 9q21-q22 locus, with linkage of visual migraine aura in 36 Finnish families. Is this a coincidence, or evidence for a migraine–epilepsy comorbidity gene?
Comorbidity is defined as the co-occurrence of 2 or more separate disorders more than expected by chance. The comorbidity of migraine and epilepsy highlighted in the article by Tikka-Kleemola et al. is well-established. The relationships between migraine and epilepsy can also be viewed as part of a clustered network of multiple comorbid neurologic and psychiatric conditions. Overlapping relationships among migraine, epilepsy, major depression, and suicidality have been identified in both cross-sectional and case-control or prospective studies.3 Cross-sectional studies show associations between anxiety disorders and both epilepsy and migraine.4–7 Examination of such comorbidity clusters can illuminate shared pathophysiology, and can have profound implications for diagnosis, prognosis, and treatment.
There is strong evidence that the relationships among these comorbid disorders are bidirectional. Depression and suicidality are not only more frequent in prevalent epilepsy, they have been shown to precede the onset of seizures8–10 and to occur more often than in controls following epilepsy onset.11 The relationship between migraine and epilepsy is also bidirectional; the risk …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen